## **Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

- 1. (Currently amended) A pharmaceutical composition useful for treating a hematological cancer in a mammal, <u>consisting essentially of comprising</u> (A) <u>at least one</u> [[an]] arsenic sulfide compound that is substantially free of arsenic impurities, and (B) a pharmaceutically acceptable carrier or excipient.
  - 2. (Canceled)
  - 3. (Canceled)
  - 4. (Canceled)
- 5. (Original) The pharmaceutical composition of claim 1, wherein said mammal is a human.
- 6. (Original) The pharmaceutical composition of claim 1, wherein the arsenic sulfide compound is selected from the group consisting of As<sub>2</sub>S<sub>2</sub>, As<sub>2</sub>S<sub>3</sub>, As<sub>2</sub>S<sub>5</sub> and As<sub>4</sub>S<sub>4</sub>.
- 7. (Original) The pharmaceutical composition of claim 6, wherein the arsenic sulfide compound is  $As_4S_4$ .
- 8. (Original) The pharmaceutical composition of claim 1, wherein the amount of said arsenic sulfide compound is from about 100 mg to about 2 g.
- 9. (Previously presented) The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable carrier or excipient is a plant semen.
- 10. (Previously presented) The pharmaceutical composition of claim 1, wherein the plant semen is *seman platycladi*.

- 11. (Original) The pharmaceutical composition of claim 1, further comprising an effective amount of an arsenious compound, wherein the arsenic sulfide compound and the arsenious compound are not the same compound.
- 12. (Previously presented) The pharmaceutical composition of claim 11, wherein the arsenious compound is selected from the group consisting of  $As_2S_2$ ,  $As_2S_3$ ,  $As_2S_5$ , and  $As_4S_4$ .
- 13. (Original) The pharmaceutical composition of claim 1, further comprising an effective amount of a therapeutic agent selected from the group consisting of mustard compounds, nitrogen mustard, chliorambucil, melphalan, cyclophosphamide busulfan, 6-mercaptopurine, 6-thioguanine, cytarabine, cytosine arabinoside, 5-fluorouracil, floxuridine, methotrexate, vincristine, vinblastine, taxol, etoposide, temiposide, dactinomycin, daunorubicin, doxorubicin, epirubicin, mitoxantron, bleomycin, mitomycin, cisplatin carboplatin, estramustine phosphate, hydroxyurea, BCNU, procarbazine, VM-26 (vumon), interferons and all-trans retinoic acid.
  - 14. (Canceled)
  - 15.-55. (Canceled)
- 56. (Previously presented) The pharmaceutical composition according to claim 1, wherein said pharmaceutical composition contains less than 0.15% arsenic trioxide.
- 57. (Previously presented) The pharmaceutical composition according to claim 1, wherein said pharmaceutical composition contains less than 0.1% arsenic trioxide.
- 58. (Previously presented) The pharmaceutical composition according to claim 13, wherein said pharmaceutical composition contains less than 0.15% arsenic trioxide.
- 59. (Previously presented) The pharmaceutical composition according to claim 13, wherein said pharmaceutical composition contains less than 0.1% arsenic trioxide.
- 60. (Previously presented) The method of claim 1, wherein the hematological cancer is selected from the group consisting of acute lymphoblastic leukemia, acute

lymphoblastic B-cell leukemia, acute lymphoblastic T-cell leukemia, acute nonlymphoblastic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute monoblastic leukemia, acute erythroleukemic leukemia, acute megakaryoblastic leukemia, chronic myelocytic leukemia, myelodysplastic syndrome, refractory anemia with excessive blast (RAEB) and RAEB in transformation to leukemia (RAEB-T), and chronic myelo-monocytic leukemia.

- 61. (Previously presented) The method of claim 1, wherein the pharmaceutical composition is formulated for oral delivery to a human.
  - 62. (Canceled)